AbbVie received two positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for RINVOQ (upadacitinib). The committee recommended approval for treating adults and adolescents with non-segmental vitiligo and severe alopecia areata. The European Commission expects to issue a final decision in the coming months.
If approved for vitiligo, RINVOQ would be the first systemic treatment for the condition in the European Union. These recommendations represent a key step in expanding AbbVie's immunology portfolio.
AbbVie stock (ABBV) rose approximately 4.2% following the announcement. The shares traded with higher-than-usual volume during the session. This gain marked the fifth consecutive day of growth for the stock.